CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 60 enrolled
Drug / intervention
Sunitinib +1 moredrug
Likely dose
Sunitinib 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02060370
NCT02060370Phase 2Completed
CompareCT.gov

A Phase II Study of Alternative Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma (mRCC)

M.D. Anderson Cancer Center·interventional·Posted Feb 12, 2014·Updated Feb 27, 2020

In Brief

A Phase 2 clinical trial evaluating Sunitinib and Questionnaire for Genitourinary Cancer and Kidney Cancer. Completed, enrolled 60 participants across 5 sites.

Detailed Summary

The goal of this clinical research study is to learn more about the safety of giving sunitinib to patients with metastatic kidney cancer for 2 weeks followed by 1 week in which they receive no drug. Researchers want to learn more about the side effects of the drug and the effects of a different dosing schedule.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGenitourinary Cancer, Kidney Cancer
CountriesUnited States
CollaboratorsPfizer

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedFeb 12, 2014
Enrollment StartAug 1, 2014
Primary CompletionJan 2, 2019
TodayJul 1, 2026
Enrollment to primary: 4.4 yearsPosted 12.4 years ago

Interventions

Sunitinibdrug

Starting dose: 50 mg by mouth daily given for 2 weeks "on" followed by 1 week "off". 1 cycle is 6 weeks.

Questionnairebehavioral

Questionnaire completion on Day 1 of Cycle 1, and on Day 35 of Cycles 2, 4, and 6.